Abstract

Photothermal therapy as a physical therapeutic approach for the localized ablation of malignant tissues has greatly attracted research interests due to its negligible systemic effects. Among various photosensitizer, IR-780 iodide as a near-infrared (NIR) fluorescent dye which is limited its further applicability in the clinic due to its low bioavailability. In this work, we developed folic acid (FA) modified bovine serum albumin (BSA) nanoparticles (FA-DINPs) that co-encapsulated chemotherapeutic compound (doxorubicin) and IR-780 for synergistic chemo-photothermal therapy using a modified desolvation method, which would facilitate clinical translation. The achieved FA-DINPs were in the size of 178 ± 5.82 nm and showed excellent photothermal effect. Furthermore, the FA-DINPs could increase drug release by laser irradiation, and enhanced cellular uptake through the FA receptor-mediated endocytosis. Our results also demonstrated that FA-DINPs exhibited remarkable cytotoxicity to cells upon NIR laser irradiation. Moreover, after laser irradiation, FA-DINPs achieved minimal systemic toxicity and high tumor inhibition efficacy without any regrowth in vivo. Therefore, our study provided a promising strategy for cancer synergistic chemo-photothermal therapy.

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.